{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:46:17Z","timestamp":1777661177299,"version":"3.51.4"},"reference-count":59,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003625","name":"Ministry of Health and Welfare","doi-asserted-by":"publisher","award":["RS-2025-02214485"],"award-info":[{"award-number":["RS-2025-02214485"]}],"id":[{"id":"10.13039\/501100003625","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.biopha.2025.118533","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T10:29:47Z","timestamp":1757500187000},"page":"118533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Oral nanoformulation of a host-directed antiviral niclosamide effectively treats severe fever with thrombocytopenia syndrome"],"prefix":"10.1016","volume":"191","author":[{"given":"Satabdi","family":"Acharya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hae-mi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chongkai","family":"Zhai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsenddari","family":"Ganbold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hyeon Jin","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Tshool","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"16","key":"10.1016\/j.biopha.2025.118533_bib1","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1056\/NEJMoa1010095","article-title":"Fever with thrombocytopenia associated with a novel bunyavirus in China","volume":"364","author":"Yu","year":"2011","journal-title":"N. Engl. J. Med."},{"issue":"18","key":"10.1016\/j.biopha.2025.118533_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e37907","article-title":"Association of gastrointestinal symptoms with mortality in patients with severe fever with thrombocytopenia syndrome","volume":"10","author":"Zhang","year":"2024","journal-title":"Heliyon"},{"issue":"4","key":"10.1016\/j.biopha.2025.118533_bib3","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.joad.2015.06.004","article-title":"Acute viral hemorrhage disease: a summary on new viruses","volume":"4","author":"Wiwanitkit","year":"2015","journal-title":"J. Acute Dis."},{"issue":"1","key":"10.1016\/j.biopha.2025.118533_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3390\/v13010010","article-title":"Prognostic factors of severe fever with thrombocytopenia syndrome in South Korea","volume":"13","author":"Kim","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2025.118533_bib5","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fmicb.2020.00150","article-title":"Antiviral drugs against severe fever with thrombocytopenia syndrome virus infection","volume":"11","author":"Takayama-Ito","year":"2020","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.biopha.2025.118533_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-015-0412-3","article-title":"Combination effects of ribavirin and interferons on severe fever with thrombocytopenia syndrome virus infection","volume":"12","author":"Shimojima","year":"2015","journal-title":"Virol. J."},{"issue":"1","key":"10.1016\/j.biopha.2025.118533_bib7","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00061-15","article-title":"Efficacy of T-705 (Favipiravir) in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus","volume":"1","author":"Tani","year":"2016","journal-title":"MSphere"},{"issue":"3","key":"10.1016\/j.biopha.2025.118533_bib8","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1177\/2040206617740303","article-title":"Establishment of an antiviral assay system and identification of severe fever with thrombocytopenia syndrome virus inhibitors","volume":"25","author":"Baba","year":"2017","journal-title":"Antivir. Chem. Chemother."},{"issue":"9","key":"10.1016\/j.biopha.2025.118533_bib9","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41422-019-0214-z","article-title":"Calcium channel blockers reduce severe fever with thrombocytopenia syndrome virus (SFTSV) related fatality","volume":"29","author":"Li","year":"2019","journal-title":"Cell Res."},{"issue":"4","key":"10.1016\/j.biopha.2025.118533_bib10","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3390\/v11040385","article-title":"Screening of an FDA-approved drug library with a two-tier system identifies an entry inhibitor of severe fever with thrombocytopenia syndrome virus","volume":"11","author":"Yuan","year":"2019","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.biopha.2025.118533_bib11","doi-asserted-by":"crossref","first-page":"940","DOI":"10.3390\/v15040940","article-title":"Recent advances in the study of the immune escape mechanism of SFTSV and its therapeutic agents","volume":"15","author":"Chen","year":"2023","journal-title":"Viruses"},{"key":"10.1016\/j.biopha.2025.118533_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2021.116356","article-title":"Antiviral strategies targeting host factors and mechanisms obliging+ ssRNA viral pathogens","volume":"46","author":"Mahajan","year":"2021","journal-title":"Bioorg. Med. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2025.118533_bib13","doi-asserted-by":"crossref","first-page":"568","DOI":"10.3390\/v15020568","article-title":"Targeting human proteins for antiviral drug discovery and repurposing efforts: a focus on protein kinases","volume":"15","author":"Hajjo","year":"2023","journal-title":"Viruses"},{"issue":"39","key":"10.1016\/j.biopha.2025.118533_bib14","doi-asserted-by":"crossref","first-page":"2305148","DOI":"10.1002\/smll.202305148","article-title":"The next generation COVID-19 antiviral; niclosamide-based inorganic nanohybrid system kills SARS-CoV-2","volume":"20","author":"Choi","year":"2024","journal-title":"Small"},{"issue":"5","key":"10.1016\/j.biopha.2025.118533_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2023.106973","article-title":"Oral delivery of a host-directed antiviral, niclosamide, as a cholate-coated nanoformulation","volume":"62","author":"Zhai","year":"2023","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"46","key":"10.1016\/j.biopha.2025.118533_bib16","doi-asserted-by":"crossref","first-page":"14541","DOI":"10.1021\/acs.nanolett.4c02845","article-title":"Insight into preventing global dengue spread: nanoengineered niclosamide for viral infections","volume":"24","author":"Rejinold","year":"2024","journal-title":"Nano Lett."},{"key":"10.1016\/j.biopha.2025.118533_bib17","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s12250-017-3953-3","article-title":"Isolation, characterization, and phylogenic analysis of three new severe fever with thrombocytopenia syndrome bunyavirus strains derived from hubei province, China","volume":"32","author":"Zhang","year":"2017","journal-title":"Virol. Sin."},{"issue":"1","key":"10.1016\/j.biopha.2025.118533_bib18","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/s41392-021-00541-3","article-title":"Clinical effect and antiviral mechanism of T-705 in treating severe fever with thrombocytopenia syndrome","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2025.118533_bib19","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1093\/infdis\/jit603","article-title":"The first identification and retrospective study of severe fever with thrombocytopenia syndrome in Japan","volume":"209","author":"Takahashi","year":"2014","journal-title":"J. Infect. Dis."},{"issue":"8","key":"10.1016\/j.biopha.2025.118533_bib20","doi-asserted-by":"crossref","first-page":"8993","DOI":"10.18632\/oncotarget.7113","article-title":"Preclinical evaluation of a nanoformulated antihelminthic, niclosamide, in ovarian cancer","volume":"7","author":"Lin","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"10.1016\/j.biopha.2025.118533_bib21","doi-asserted-by":"crossref","DOI":"10.1093\/pnasnexus\/pgac024","article-title":"Exploration of immunological responses underpinning severe fever with thrombocytopenia syndrome virus infection reveals IL-6 as a therapeutic target in an immunocompromised mouse model","volume":"1","author":"Bryden","year":"2022","journal-title":"PNAS Nexus"},{"issue":"3","key":"10.1016\/j.biopha.2025.118533_bib22","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.4049\/jimmunol.179.3.1855","article-title":"Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice","volume":"179","author":"Gupta","year":"2007","journal-title":"J. Immunol."},{"issue":"25","key":"10.1016\/j.biopha.2025.118533_bib23","doi-asserted-by":"crossref","first-page":"10053","DOI":"10.1073\/pnas.1120246109","article-title":"Pathogenesis of emerging severe fever with thrombocytopenia syndrome virus in C57\/BL6 mouse model","volume":"109","author":"Jin","year":"2012","journal-title":"Proc. Natl. Acad. Sci. U. S. A"},{"issue":"1","key":"10.1016\/j.biopha.2025.118533_bib24","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01825-16","article-title":"CD8+ t cells and macrophages regulate pathogenesis in a mouse model of Middle East respiratory syndrome","volume":"91","author":"Coleman","year":"2017","journal-title":"J. Virol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118533_bib25","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1038\/s41467-019-11815-4","article-title":"Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets","volume":"10","author":"Kwak","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2025.118533_bib26","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jcv.2011.09.031","article-title":"Early diagnosis of novel SFTS bunyavirus infection by quantitative real-time RT-PCR assay","volume":"53","author":"Sun","year":"2012","journal-title":"J. Clin. Virol."},{"key":"10.1016\/j.biopha.2025.118533_bib27","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.118458","article-title":"Niclosamide-loaded polymeric micelles ameliorate hepatocellular carcinoma in vivo through targeting wnt and notch pathways","volume":"261","author":"Zeyada","year":"2020","journal-title":"Life Sci."},{"issue":"6","key":"10.1016\/j.biopha.2025.118533_bib28","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2174\/138620711795767802","article-title":"The design and application of target-focused compound libraries","volume":"14","author":"John Harris","year":"2011","journal-title":"Comb. Chem. High. Throughput Screen"},{"key":"10.1016\/j.biopha.2025.118533_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114507","article-title":"Oral drug delivery strategies for development of poorly water soluble drugs in paediatric patient population","volume":"190","author":"Salunke","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"4","key":"10.1016\/j.biopha.2025.118533_bib30","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/pharmaceutics15041179","article-title":"Recent advances in biocompatible ionic liquids in drug formulation and delivery","volume":"15","author":"Moshikur","year":"2023","journal-title":"Pharmaceutics"},{"issue":"13","key":"10.1016\/j.biopha.2025.118533_bib31","doi-asserted-by":"crossref","first-page":"6410","DOI":"10.1039\/D1NR00309G","article-title":"Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection","volume":"13","author":"Hobson","year":"2021","journal-title":"Nanoscale"},{"key":"10.1016\/j.biopha.2025.118533_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.nano.2019.102089","article-title":"Tumor-specific delivery of a paclitaxel-loading HSA-haemin nanoparticle for cancer treatment","volume":"23","author":"Chung","year":"2020","journal-title":"Nanomed. Nanotechnol. Biol. Med."},{"key":"10.1016\/j.biopha.2025.118533_bib33","doi-asserted-by":"crossref","first-page":"104","DOI":"10.3389\/fmicb.2017.00104","article-title":"Animal models of emerging tick-borne phleboviruses: determining target cells in a lethal model of SFTSV infection","volume":"8","author":"Matsuno","year":"2017","journal-title":"Front. Microbiol."},{"issue":"1","key":"10.1016\/j.biopha.2025.118533_bib34","doi-asserted-by":"crossref","first-page":"2430","DOI":"10.1080\/21505594.2021.1972201","article-title":"Roborovski hamster (Phodopus roborovskii) strain SH101 as a systemic infection model of SARS-CoV-2","volume":"12","author":"Zhai","year":"2021","journal-title":"Virulence"},{"key":"10.1016\/j.biopha.2025.118533_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12985-016-0669-1","article-title":"Correlation of cytokine level with the severity of severe fever with thrombocytopenia syndrome","volume":"14","author":"Liu","year":"2017","journal-title":"Virol. J."},{"issue":"7","key":"10.1016\/j.biopha.2025.118533_bib36","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/infdis\/jis452","article-title":"Host cytokine storm is associated with disease severity of severe fever with thrombocytopenia syndrome","volume":"206","author":"Sun","year":"2012","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.biopha.2025.118533_bib37","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.2147\/DDDT.S473178","article-title":"Revisiting niclosamide formulation approaches\u2013a pathway toward drug repositioning","author":"Jug","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2025.118533_bib38","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.3390\/microorganisms11092309","article-title":"Emerging tick-borne dabie bandavirus: virology, epidemiology, and prevention","volume":"11","author":"Kim","year":"2023","journal-title":"Microorganisms"},{"issue":"24","key":"10.1016\/j.biopha.2025.118533_bib39","doi-asserted-by":"crossref","first-page":"16116","DOI":"10.3390\/ijms232416116","article-title":"Niclosamide as a promising therapeutic player in human cancer and other diseases","volume":"23","author":"Wang","year":"2022","journal-title":"Int. J. Mol. Sci."},{"issue":"10","key":"10.1016\/j.biopha.2025.118533_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002976","article-title":"Niclosamide is a proton carrier and targets acidic endosomes with broad antiviral effects","volume":"8","author":"Jurgeit","year":"2012","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.biopha.2025.118533_bib41","doi-asserted-by":"crossref","first-page":"8682","DOI":"10.1038\/s41598-019-45095-1","article-title":"Neutralization of acidic intracellular vesicles by niclosamide inhibits multiple steps of the dengue virus life cycle in vitro","volume":"9","author":"Jung","year":"2019","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.biopha.2025.118533_bib42","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.virs.2023.01.008","article-title":"Identification of niclosamide as a novel antiviral agent against porcine epidemic diarrhea virus infection by targeting viral internalization","volume":"38","author":"Wang","year":"2023","journal-title":"Virol. Sin."},{"issue":"10","key":"10.1016\/j.biopha.2025.118533_bib43","doi-asserted-by":"crossref","first-page":"2616","DOI":"10.1021\/acsinfecdis.0c00217","article-title":"JMX0207, a niclosamide derivative with improved pharmacokinetics, suppresses zika virus infection both in vitro and in vivo","volume":"6","author":"Li","year":"2020","journal-title":"ACS Infect. Dis."},{"issue":"1","key":"10.1016\/j.biopha.2025.118533_bib44","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/jbm.a.36788","article-title":"Injectable pegylated niclosamide (polyethylene glycol-modified niclosamide) for cancer therapy","volume":"108","author":"Ma","year":"2020","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.biopha.2025.118533_bib45","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.msec.2017.03.161","article-title":"Design, synthesis and characterization of poly (methacrylic acid-niclosamide) and its effect on arterial function","volume":"77","author":"Ma","year":"2017","journal-title":"Mater. Sci. Eng. C"},{"key":"10.1016\/j.biopha.2025.118533_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.micromeso.2021.111394","article-title":"Niclosamide encapsulated in mesoporous silica and geopolymer: a potential oral formulation for COVID-19","volume":"326","author":"Piao","year":"2021","journal-title":"Microporous Mesoporous Mater."},{"issue":"2","key":"10.1016\/j.biopha.2025.118533_bib47","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1081\/DDC-120028718","article-title":"Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations","volume":"30","author":"Gao","year":"2004","journal-title":"Drug Dev. Ind. Pharm."},{"issue":"6","key":"10.1016\/j.biopha.2025.118533_bib48","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2025.118533_bib49","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jconrel.2017.01.014","article-title":"BCS class IV drugs: highly notorious candidates for formulation development","volume":"248","author":"Ghadi","year":"2017","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.biopha.2025.118533_bib50","doi-asserted-by":"crossref","first-page":"S41","DOI":"10.1016\/S0169-409X(01)00179-X","article-title":"Predicting the impact of physiological and biochemical processes on oral drug bioavailability","volume":"50","author":"Agoram","year":"2001","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.biopha.2025.118533_bib51","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1208\/s12249-014-0252-2","article-title":"Interpolyelectrolyte complexes of Eudragit\u00ae EPO with hypromellose acetate succinate and Eudragit\u00ae EPO with hypromellose phthalate as potential carriers for oral controlled drug delivery","volume":"16","author":"Jeganathan","year":"2015","journal-title":"AAPS PharmSciTech"},{"issue":"5","key":"10.1016\/j.biopha.2025.118533_bib52","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1039\/D0TB02606A","article-title":"A novel cyanoacrylate-based matrix excipient in HPMCP capsules forms a sustained intestinal delivery system for orally administered drugs with enhanced absorption efficiency","volume":"9","author":"Song","year":"2021","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.biopha.2025.118533_bib53","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.jconrel.2020.07.034","article-title":"Bile acid transporter-mediated oral drug delivery","volume":"327","author":"Deng","year":"2020","journal-title":"J. Contr. Release"},{"issue":"29","key":"10.1016\/j.biopha.2025.118533_bib54","doi-asserted-by":"crossref","first-page":"9952","DOI":"10.3748\/wjg.v20.i29.9952","article-title":"Therapeutic uses of animal biles in traditional Chinese Medicine: an ethnopharmacological, biophysical chemical and medicinal review","volume":"20","author":"Wang","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.biopha.2025.118533_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119252","article-title":"The bile acid TUDCA and neurodegenerative disorders: an overview","volume":"272","author":"Zangerolamo","year":"2021","journal-title":"Life Sci."},{"issue":"1","key":"10.1016\/j.biopha.2025.118533_bib56","doi-asserted-by":"crossref","DOI":"10.1111\/apha.13227","article-title":"Tauroursodeoxycholic acid (TUDCA) abolishes chronic high salt-induced renal injury and inflammation","volume":"226","author":"De Miguel","year":"2019","journal-title":"Acta Physiol."},{"issue":"7","key":"10.1016\/j.biopha.2025.118533_bib57","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1042\/CS20220674","article-title":"Potential therapeutic action of tauroursodeoxycholic acid against cholestatic liver injury via hepatic Fxr\/Nrf2 and CHOP-DR5-caspase-8 pathway","volume":"137","author":"Song","year":"2023","journal-title":"Clin. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2025.118533_bib58","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.1016\/j.apsb.2022.02.002","article-title":"Why 90% of clinical drug development fails and how to improve it?","volume":"12","author":"Sun","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.biopha.2025.118533_bib59","doi-asserted-by":"crossref","first-page":"18911","DOI":"10.1038\/s41598-019-54849-w","article-title":"Improving the odds of drug development success through human genomics: modelling study","volume":"9","author":"Hingorani","year":"2019","journal-title":"Sci. Rep."}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225007279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332225007279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T01:48:50Z","timestamp":1772848130000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332225007279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":59,"alternative-id":["S0753332225007279"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118533","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oral nanoformulation of a host-directed antiviral niclosamide effectively treats severe fever with thrombocytopenia syndrome","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2025.118533","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"118533"}}